FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2796354014> ?p ?o ?g. }

• W2796354014 endingPage "569" @default.
• W2796354014 startingPage "561" @default.
• W2796354014 abstract "Infections represent one of the major concerns regarding the utilization of ruxolitinib (RUX) in patients with myelofibrosis. With the aim to investigate epidemiology, outcome and risk factors for infections in RUX-exposed patients, we collected clinical and laboratory data of 446 myelofibrosis patients treated with RUX between June 2011 and November 2016 in 23 European Hematology Centers. After a median RUX exposure of 23.5 months (range, 1-56), 123 patients (28%) experienced 161 infectious events (grades 3-4 32%, fatal 9%), for an incidence rate of 17 cases per 100 pts/y. The rate of infections tended to decrease over time: 14% of patients developed the first infection within 6 months, 5% between 6 and 12 months, 3.7% between 12 and 18 months, 3.4% between 18 and 24 months, and 7.9% thereafter (P < .0001). Respiratory tract infections were more frequently observed (81 events, 50%), and bacteria were the most frequent etiological agents (68.9%). However, also viral (14.9%) and fungal infections (2.5%) were observed. In multivariate analysis, previous infectious event (HR 2.54; 95% CI, 1.51-4.28; P = .0005) and high international prognostic score system category (IPSS) (HR 1.53; 95% CI, 1.07-2.20; P = .021) significantly correlated with higher infectious risk. On the contrary, spleen reduction ≥50% from baseline after 3 months of treatment (P = .02) was associated with better infection-free survival. Taken together, these findings reinforce the concept of disease severity as the most important risk factor for infections, and describe, for the first time, that a positive therapeutic effect in reducing splenomegaly may also reduce subsequent infectious complications." @default.
• W2796354014 created "2018-04-13" @default.
• W2796354014 creator A5002133396 @default.
• W2796354014 creator A5006023644 @default.
• W2796354014 creator A5007773747 @default.
• W2796354014 creator A5008040655 @default.
• W2796354014 creator A5008566093 @default.
• W2796354014 creator A5009267255 @default.
• W2796354014 creator A5014739728 @default.
• W2796354014 creator A5020333760 @default.
• W2796354014 creator A5021123903 @default.
• W2796354014 creator A5026430732 @default.
• W2796354014 creator A5026992937 @default.
• W2796354014 creator A5037607824 @default.
• W2796354014 creator A5037637576 @default.
• W2796354014 creator A5045651843 @default.
• W2796354014 creator A5046461065 @default.
• W2796354014 creator A5058392949 @default.
• W2796354014 creator A5058761919 @default.
• W2796354014 creator A5060107199 @default.
• W2796354014 creator A5062047451 @default.
• W2796354014 creator A5066257986 @default.
• W2796354014 creator A5069887195 @default.
• W2796354014 creator A5070044155 @default.
• W2796354014 creator A5071926851 @default.
• W2796354014 creator A5074166501 @default.
• W2796354014 creator A5076954137 @default.
• W2796354014 creator A5078900656 @default.
• W2796354014 creator A5079398488 @default.
• W2796354014 creator A5080563685 @default.
• W2796354014 creator A5085994414 @default.
• W2796354014 creator A5086845182 @default.
• W2796354014 creator A5089760320 @default.
• W2796354014 creator A5090857723 @default.
• W2796354014 date "2018-04-06" @default.
• W2796354014 modified "2023-10-13" @default.
• W2796354014 title "Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients" @default.
• W2796354014 cites W1483308173 @default.
• W2796354014 cites W1582185909 @default.
• W2796354014 cites W1821913351 @default.
• W2796354014 cites W1966376466 @default.
• W2796354014 cites W1985964215 @default.
• W2796354014 cites W2000799069 @default.
• W2796354014 cites W2001280008 @default.
• W2796354014 cites W2006467209 @default.
• W2796354014 cites W2008799537 @default.
• W2796354014 cites W2010298229 @default.
• W2796354014 cites W2010507912 @default.
• W2796354014 cites W2012249056 @default.
• W2796354014 cites W2020294706 @default.
• W2796354014 cites W2031251938 @default.
• W2796354014 cites W2039028980 @default.
• W2796354014 cites W2054787206 @default.
• W2796354014 cites W2070929302 @default.
• W2796354014 cites W2078678444 @default.
• W2796354014 cites W2083490754 @default.
• W2796354014 cites W2083736769 @default.
• W2796354014 cites W2085148377 @default.
• W2796354014 cites W2087172868 @default.
• W2796354014 cites W2107398329 @default.
• W2796354014 cites W2110316381 @default.
• W2796354014 cites W2115351357 @default.
• W2796354014 cites W2118323591 @default.
• W2796354014 cites W2121743767 @default.
• W2796354014 cites W2122395736 @default.
• W2796354014 cites W2127559749 @default.
• W2796354014 cites W2141249732 @default.
• W2796354014 cites W2145706987 @default.
• W2796354014 cites W2151734278 @default.
• W2796354014 cites W2154692607 @default.
• W2796354014 cites W2157066112 @default.
• W2796354014 cites W2166734004 @default.
• W2796354014 cites W2330245393 @default.
• W2796354014 cites W2339658711 @default.
• W2796354014 cites W2473076003 @default.
• W2796354014 cites W2529276663 @default.
• W2796354014 cites W2559562829 @default.
• W2796354014 cites W2724288088 @default.
• W2796354014 cites W2731255636 @default.
• W2796354014 cites W2980804987 @default.
• W2796354014 doi "https://doi.org/10.1002/hon.2509" @default.
• W2796354014 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29624703" @default.
• W2796354014 hasPublicationYear "2018" @default.
• W2796354014 type Work @default.
• W2796354014 sameAs 2796354014 @default.
• W2796354014 citedByCount "44" @default.
• W2796354014 countsByYear W27963540142018 @default.
• W2796354014 countsByYear W27963540142019 @default.
• W2796354014 countsByYear W27963540142020 @default.
• W2796354014 countsByYear W27963540142021 @default.
• W2796354014 countsByYear W27963540142022 @default.
• W2796354014 countsByYear W27963540142023 @default.
• W2796354014 crossrefType "journal-article" @default.
• W2796354014 hasAuthorship W2796354014A5002133396 @default.
• W2796354014 hasAuthorship W2796354014A5006023644 @default.
• W2796354014 hasAuthorship W2796354014A5007773747 @default.
• W2796354014 hasAuthorship W2796354014A5008040655 @default.
• W2796354014 hasAuthorship W2796354014A5008566093 @default.

• next